448 results
Page 9 of 23
8-K
EX-99.1
pme26 rk3plv95undzb
8 Sep 14
Other Events
12:00am
8-K
EX-99.1
dgk5dvzwj p4fdi
9 Jul 14
Anoro® Ellipta® (umeclidinium/vilanterol) approved in Australia for Chronic Obstructive Pulmonary Disease
12:00am
8-K
EX-99
7g4s0b rc0yocdt9v3
7 Jul 14
Other Events
12:00am
8-K
EX-10.5
eva5bwuf
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-99.1
4xhmj5l08 df9c
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.1
ktwz6 1mvw
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.4
gaz08ys4du4g8el41y
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-99
bd00vjsem9 09
28 Apr 14
Financial Statements and Exhibits
12:00am
8-K
EX-99.1
wuipsavh4jzpoakv
22 Apr 14
Breo™Ellipta® (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and Chronic Obstructive Pulmonary Disease
12:00am
8-K
EX-10.8
ee823a0knymtp6 umh
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.4
b5kfp
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.1
dqkhf4476slirvisp
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
CORRESP
95ebpkta7u7fxlab
15 Apr 14
Correspondence with SEC
12:00am
8-K
EX-99.1
q9yc8 2xvtpsz
9 Apr 14
Regulation FD Disclosure
12:00am